First, discovering TERT promoter mutations in thyroid nodules that represent a malignant disease, however, in adult DTCs, including FTCs and PTCs, the prevalence of the TERT promoter mutation is <25% in Western countries while can be lowered to <3% in certain populations,11 which constitutes a relative low sensitivity for this biomarker. The gene discussed is TERT; the disease is thyroid nodule.